Skip to main navigation
Tenaya Therapeutics
  • Careers at Tenaya
  • Contact Us
  • Leadership
  • Our Science
    • Platforms
    • Capabilities
    • Collaborations
    • Publications & Presentations
  • Our Programs
    • Pipeline
    • Programs
  • Patients
    • Elevating Patient Voices
    • Advocacy at Tenaya
    • Clinical Studies
    • Gene Therapy for Cardiomyopathies
    • Advocacy Partners
  • Investors
    • News & Events
      • Press Releases
      • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • IR Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
  • HCP Resource Center
    • Genetic Medicine Primer
      • About Gene Therapy
    • TN-201 for MYBPC3– associated HCM
      • Hypertrophic Cardiomyopathy and Genetics
      • How TN-201 Works
      • MyPEAK-1 Phase 1b/2 Clinical Trial
      • Tenaya’s Non-interventional Studies for MYBPC3 HCM
      • Webinars
      • FAQ’s
    • TN-401 for PKP2– associated ARVC
      • ARVC and Genetics
      • How TN-401 works
      • RIDGE-1 Phase 1b Clinical Trial
      • Tenaya’s Non-interventional Study for PKP2-Associated ARVC
      • FAQ’s

Investor Portal

Nov 04, 2026
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Sep 14, 2026
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Sep 03, 2026
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
Aug 05, 2026
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 04, 2026
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Jul 14, 2026
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jun 29, 2026
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Jun 03, 2026
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Jun 02, 2026
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
May 29, 2026
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 18
RSS Feeds
Email Alerts
Contact IR
Print

Privacy Policy | Cookie Policy | Terms of Use | Community Guidelines
© 2026 Tenaya Therapeutics. All rights reserved.